<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01588509</url>
  </required_header>
  <id_info>
    <org_study_id>20110253</org_study_id>
    <nct_id>NCT01588509</nct_id>
  </id_info>
  <brief_title>Transition From Alendronate to Romosozumab (AMG 785)</brief_title>
  <official_title>An Open-label, Randomized Study to Estimate the Percent Change From Baseline in Lumbar Spine Bone Mineral Density After 3 Months of AMG 785 Administration in Postmenopausal Women With Low Bone Mineral Density Previously Treated With Alendronate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to estimate the percent change from baseline in lumbar spine
      bone mineral density (BMD) following multiple-dose administrations of romosozumab in
      postmenopausal women with low BMD previously treated with alendronate.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 30, 2012</start_date>
  <completion_date type="Actual">November 21, 2012</completion_date>
  <primary_completion_date type="Actual">November 21, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in lumbar spine bone mineral density (BMD)</measure>
    <time_frame>Change from baseline at day 85</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in total hip and femoral neck BMD</measure>
    <time_frame>Change from baseline at day 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum type 1 aminoterminal propeptide (P1NP) measurements</measure>
    <time_frame>Change from baseline at day 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment-emergent adverse events to include clinically significant changes in chemistry, hematology, physical examinations, electrocardiograms, and incidences of subjects who develop anti-AMG 785 antibodies</measure>
    <time_frame>Up to day 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean (SD) serum concentration of AMG 785</measure>
    <time_frame>Baseline through day 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum C-telopeptide (sCTX) measurements</measure>
    <time_frame>Change from baseline at day 85</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Romosozumab 140 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received romosozumab 140 mg administered subcutaneously once a month for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Romosozumab 210 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received romosozumab 210 mg administered subcutaneously once a month for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Romosozumab</intervention_name>
    <description>Administered by subcutaneous injection</description>
    <arm_group_label>Romosozumab 140 mg</arm_group_label>
    <arm_group_label>Romosozumab 210 mg</arm_group_label>
    <other_name>AMG 785</other_name>
    <other_name>EVENITY™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women, defined as no vaginal bleeding or spotting for ≥ 12 months

          -  Low bone mineral density at screening [defined by a bone mineral density (BMD) T-score
             ≤ -2.0 and ≥ -4.0 at the lumbar spine (L1 to L4; or BMD T-score of evaluable
             vertebrae), total hip, or femoral neck]

          -  Currently taking alendronate (70 mg weekly or equivalent) exclusively for ≥ 1 year
             with verbal agreement that the subject has taken ≥ 80% of their doses with good
             tolerance

        Exclusion Criteria:

          -  History of vertebral fracture, or fragility fracture of the wrist, humerus, hip or
             pelvis after age 50; or recent bone fracture within 6 months prior to screening

          -  History of metabolic or bone disease such as Paget's disease, rheumatoid arthritis,
             osteomalacia, osteogenesis imperfecta, osteopetrosis, ankylosing spondylitis,
             Cushing's disease, hyperprolactinemia, and malabsorption syndrome

          -  Vitamin D deficiency (defined as 25-OH-VitD levels &lt; 20 ng/mL)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>West Haverstraw</city>
        <state>New York</state>
        <zip>10993</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2012</study_first_submitted>
  <study_first_submitted_qc>April 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2012</study_first_posted>
  <last_update_submitted>June 2, 2017</last_update_submitted>
  <last_update_submitted_qc>June 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AMG 785, bone mineral density, alendronate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alendronate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

